Systematic medical assessment, referral and treatment for diabetes care in China using lay family health promoters: protocol for the SMARTDiabetes cluster randomised controlled trialReportar como inadecuado




Systematic medical assessment, referral and treatment for diabetes care in China using lay family health promoters: protocol for the SMARTDiabetes cluster randomised controlled trial - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Implementation Science

, 11:116

First Online: 17 August 2016Received: 12 July 2016Accepted: 04 August 2016DOI: 10.1186-s13012-016-0481-8

Cite this article as: Peiris, D., Sun, L., Patel, A. et al. Implementation Sci 2015 11: 116. doi:10.1186-s13012-016-0481-8

Abstract

BackgroundType 2 diabetes T2DM affects 113.9 million people in China, the largest number of any country in the world JAMA 310:948–59, 2013. T2DM prevalence has risen dramatically from around 1 % in the 1980s to now over 10 % and is expected to continue rising. Despite the growing disease burden, few people with T2DM are achieving adequate management targets to prevent complications. Health system infrastructure in China is struggling to meet these gaps in care, and innovative, cost-effective and affordable solutions are needed. One promising strategy that may be particularly relevant to the Chinese context is improving support for lay family members to care for their relatives with T2DM.

MethodsWe hypothesise that an interactive mobile health management system can support lay family health promoters FHP and healthcare staff to improve clinical outcomes for family members with T2DM through medical assessment, regular monitoring, lifestyle advice and the prescribing of guidelines recommended medications. This intervention will be implemented as a cluster randomised controlled trial involving 80 communities 40 communities in Beijing and 40 rural villages in Hebei province and 2000 people with T2DM. Outcome analyses will be conducted blinded to intervention allocation.

The primary outcome is the proportion of patients achieving ≥2 -ABC- goals HbA1c <7.0 %, blood pressure BP <140-80 mmHg and LDL cholesterol <100 mg-dl or 2.6 mmol-L at the end of follow-up Diabetes Care 36Supplement 1:S11-S66, 2013. Secondary outcomes include the proportion of patients achieving individual ABC targets; mean changes in HbA1c, BP, LDL, renal function serum creatinine and urinary albumin, body mass index, quality of life QOL, EQ-5D, and healthcare utilisation from baseline; and cost-effectiveness-utility of intervention. Trial outcomes will be accompanied by detailed process and economic evaluations.

Discussion The Chinese government has prioritised prevention and treatment of diabetes as 1 of 11 National Basic Public Health Services. Despite great promise for mHealth interventions to improve access to effective health care, there remains uncertainty about how this can be successfully achieved. The findings are likely to inform policy on a scalable strategy to overcome sub-optimal access to effective health care in China.

Trial registrationClinicaltrials.gov NCT02726100

KeywordsType 2 diabetes Capacity strengthening mHealth China Implementation  Download fulltext PDF



Autor: David Peiris - Lei Sun - Anushka Patel - Maoyi Tian - Beverley Essue - Stephen Jan - Puhong Zhang

Fuente: https://link.springer.com/







Documentos relacionados